

Current progress towards life changing treatments

Dr Alison Evans

Alzheimer's Research UK



Alzheimer's
Research
UK

The Power
to Defeat
Dementia

Impact of Dementia


1 in 3 people born in the UK this year will develop dementia in their lifetime.




One million people in the UK will have dementia by 2025 and this will increase to two million by 2050.



Dementia has higher health and social care costs (£11.9bn) than cancer (£5.0bn) and chronic heart disease (£2.5bn) combined.






Progress made



The research landscape: progress in dementia research capacity

The UK has the fastest growing dementia research landscape

Analysis of researchers, output and collaborations 2014-5 compared to 2008-9.



In 2008, there was **1 dementia researcher** for every **6 in cancer**



In 2015, there was **1 dementia researcher** for every **4 in cancer**

Summary of the Dementia Landscape

Public Awareness

- Increased political focus on dementia is helping to drive public awareness and support
- Much still needs to be done to improve public understanding and attitudes to dementia

Current treatments

- Currently no drugs on the market which slow or stop disease progression
- Current diagnosis relies on cognitive symptoms that occur late in the disease course

Research into Understanding the Causes of Dementia


- Neurodegenerative diseases are still poorly understood
- Investment in basic research is improving, but coming off a low baseline
- Large-scale investments like the UK DRI will hopefully provide a step change in the rate of progress

Treatment Development


- Poor disease understanding and lack of biomarkers & sensitive clinical tools have hampered drug development
- A few promising agents are in late-stage trials, but many more are needed
- Pharma are starting to reinvest through risk-share mechanisms like the Dementia Discovery Fund & the Dementia Consortium

What is Different about Dementia Drug Discovery?

The Even Longer & Risky Road to a Dementia Drug



The Impact of ARUK in the Drug Discovery, Development and Access Pipeline



Is healthcare system ready?



Alzheimer's
Research
UK

The Power
to Defeat
Dementia

Preparing for breakthroughs in dementia



Development challenges

- Measuring gradual change over the relatively short duration of a clinical trial
- Clinical trials need to be long enough to enable endpoints to be measured, or new biomarkers will need to be validated.
- Real world evidence will be important in longer term



System challenges

- The health system is not prepared for disease-modifying treatments for Alzheimer's disease



Affordability challenges

- The cost of a disease-modifying treatment is likely to be high
- A disease-modifying treatment will also potentially transform dementia treatment pathways, requiring additional infrastructure, equipment, staff training and skills.



Cultural challenges


- The NHS does not have a culture of adopting innovation quickly
- Require further education and understanding of dementia across the public and the NHS, and greater communication and collaboration across clinical disciplines.




Preparing the healthcare system for future treatments




Potential annual costs of future treatments



Value of a new treatment



Benefits of treating earlier



Dementia Access Taskforce

Alzheimer's Research UK is launching a taskforce to ensure that people with dementia can get future treatments quickly

Awareness and early diagnosis



1. Look at ideas to update understanding on Alzheimer's disease and the distinction between Alzheimer's disease, Alzheimer's dementia and other forms of dementia.
2. Scope the barriers and opportunities to moving diagnosis earlier and shifting towards molecular based diagnosis and risk profile.

Adoption and uptake

3. Understand how the UK health system could accommodate the specialist investigations required to select patients and prescribe future treatments.
4. With clinicians, help develop a framework for new services, and recommend timescales for implementation.

Value and pricing models

5. Ensure that the assessment of value of new disease-modifying treatments for dementia captures their full value
6. Develop innovative access and funding models to ensure the introduction of innovative medicines and diagnostics into the UK for Dementia.



Thank you



Alzheimer's
Research
UK

The Power
to Defeat
Dementia